Senators Mike Lee (R-UT) and Tommy Tuberville (R-AL) introduce the Homeopathic Drug Product Safety, Quality, and Transparency Act.
Eli Lilly reports Phase 3 study results showing its oral GLP-1 receptor agonist Foundayo (orforglipron) outperformed Novo Nordisk's oral semaglutide o...
Delegates at the American Medical Association's annual meeting vote to support stronger FDA oversight of synthetic peptide products, citing growing co...
FDA places a clinical hold on Quantum BioPharmas IND for its multiple sclerosis drug candidate Lucid-21-302.
Eight Mintz attorneys analyze the recent Supreme Court decision giving generic drug manufacturers a victory in an induced infringement case.
Former FDA enforcement official suggests new strategies for industry to prepare for agency inspections that rely on artificial intelligence tools.
FDA officials are seeking to bolster confidence in generic medicines, highlighting the agency's oversight of drug manufacturing, inspection programs a...
FDA launches a new effort to aggregate clinical trial data on kidney safety biomarkers, seeking pharmaceutical industry participation in a pilot progr...
